KR20080022203A - 트라넥삼산의 아실옥시알킬 카르바메이트 프로드러그, 합성방법 및 용도 - Google Patents

트라넥삼산의 아실옥시알킬 카르바메이트 프로드러그, 합성방법 및 용도 Download PDF

Info

Publication number
KR20080022203A
KR20080022203A KR1020087001522A KR20087001522A KR20080022203A KR 20080022203 A KR20080022203 A KR 20080022203A KR 1020087001522 A KR1020087001522 A KR 1020087001522A KR 20087001522 A KR20087001522 A KR 20087001522A KR 20080022203 A KR20080022203 A KR 20080022203A
Authority
KR
South Korea
Prior art keywords
substituted
trans
aminomethyl
cyclohexanecarboxylic acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020087001522A
Other languages
English (en)
Korean (ko)
Inventor
베른트 얀델라이트
윤샤오 리
노아 제랭
마크 에이 갤럽
Original Assignee
제노포트 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제노포트 인코포레이티드 filed Critical 제노포트 인코포레이티드
Publication of KR20080022203A publication Critical patent/KR20080022203A/ko
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020087001522A 2005-06-20 2006-06-20 트라넥삼산의 아실옥시알킬 카르바메이트 프로드러그, 합성방법 및 용도 Abandoned KR20080022203A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69262505P 2005-06-20 2005-06-20
US60/692,625 2005-06-20

Publications (1)

Publication Number Publication Date
KR20080022203A true KR20080022203A (ko) 2008-03-10

Family

ID=37460256

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087001522A Abandoned KR20080022203A (ko) 2005-06-20 2006-06-20 트라넥삼산의 아실옥시알킬 카르바메이트 프로드러그, 합성방법 및 용도

Country Status (15)

Country Link
US (4) US7351740B2 (https=)
EP (1) EP1919859B1 (https=)
JP (1) JP4938771B2 (https=)
KR (1) KR20080022203A (https=)
CN (1) CN101253148B (https=)
AT (1) ATE469880T1 (https=)
AU (1) AU2006262386B2 (https=)
CA (1) CA2612292C (https=)
DE (1) DE602006014694D1 (https=)
ES (1) ES2345784T3 (https=)
IL (1) IL188172A (https=)
NO (1) NO20076508L (https=)
NZ (1) NZ564468A (https=)
WO (1) WO2007002013A2 (https=)
ZA (1) ZA200800311B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
WO2007002013A2 (en) 2005-06-20 2007-01-04 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
JP5313124B2 (ja) * 2006-03-16 2013-10-09 バーテックス ファーマシューティカルズ インコーポレイテッド 立体的化合物を製造するための方法および中間体
US20090082464A1 (en) * 2007-09-07 2009-03-26 Bernd Jandeleit Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2217564A1 (en) * 2007-09-07 2010-08-18 XenoPort, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) * 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2011028234A1 (en) 2009-09-04 2011-03-10 Xenoport, Inc. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid
WO2011091164A1 (en) 2010-01-22 2011-07-28 Xenoport, Inc. Oral dosage forms having a high loading of a tranexamic acid prodrug
US8597683B2 (en) 2010-11-30 2013-12-03 Watson Pharmaceuticals, Inc. Modified release tranexamic acid formulation
WO2012121811A1 (en) * 2011-03-04 2012-09-13 Arstat, Inc. Treatment of excessive menstrual blood loss by intravaginal administration of low doses of antifibronlytic or hemostatic agent
DE202011110392U1 (de) 2011-04-12 2014-01-16 Arstat, Inc. Oral verabreichbare pharmazeutische Zusammensetzung zur behandlung von Menstruationsschmerzen, die von übermäßigem menstruellem Blutverlust begleitet sind
FI125336B (fi) * 2012-10-31 2015-08-31 Kone Corp Hissijärjestely
WO2015089626A1 (en) 2013-12-16 2015-06-25 The University Of British Columbia Self-fueled particles for propulsion through flowing aqueous fluids
EP3681479B1 (en) 2017-09-15 2024-01-31 Dyve Biosciences, Inc. Sodium bicarbonate for use in the treatment of gout and related disorders
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
JP2020090453A (ja) * 2018-12-05 2020-06-11 ポーラ化成工業株式会社 日焼け抑制用組成物
WO2022033202A1 (zh) * 2020-08-13 2022-02-17 南京海融医药科技股份有限公司 布洛芬酯类前药、药物组合物以及制备方法和应用
CN121248675A (zh) * 2020-12-31 2026-01-02 赛诺哈勃药业（成都）有限公司 一种纤溶酶抑制剂、其制备方法及应用
EP4134362B1 (en) 2021-06-29 2024-02-28 Nanjing Heron Pharmaceutical Science and Technology Co., Ltd. Ibuprofen ester derivative and emulsion formulation thereof

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996431A (en) 1953-12-16 1961-08-15 Barry Richard Henry Friable tablet and process for manufacturing same
US3402240A (en) 1957-06-25 1968-09-17 Pfizer & Co C Medicinal tablet and process of making same
US3139383A (en) 1961-06-26 1964-06-30 Norton Co Encapsulated time release pellets and method for encapsulating the same
US3499925A (en) 1964-03-23 1970-03-10 Daiichi Seiyaku Co Process for the production of trans-4-aminomethylcyclohexane - 1 - carboxylic acid
GB1364672A (en) 1971-06-09 1974-08-29 Beecham Group Ltd Penicillins
US3962414A (en) 1972-04-27 1976-06-08 Alza Corporation Structured bioerodible drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3811444A (en) 1972-12-27 1974-05-21 Alza Corp Bioerodible ocular device
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
DE2336218C3 (de) 1973-07-17 1985-11-14 Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz Orale Arzneiform
US4048222A (en) 1974-03-04 1977-09-13 Kureha Kagaku Kogyo Kabushiki Kaisha Process for preparing trans-4-aminomethyl-cyclohexane-1-carboxylic acid
US3992518A (en) 1974-10-24 1976-11-16 G. D. Searle & Co. Method for making a microsealed delivery device
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
JPS51138651A (en) 1975-05-27 1976-11-30 Kureha Chem Ind Co Ltd Process for pr eparing trans-4-aminomethyo-cyclohexane
US4055580A (en) 1975-08-22 1977-10-25 Rorer Italiana S.P.A. Derivatives of aminomethylcyclohexanecarboxylic acid
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4079038A (en) 1976-03-05 1978-03-14 Alza Corporation Poly(carbonates)
US4066747A (en) 1976-04-08 1978-01-03 Alza Corporation Polymeric orthoesters housing beneficial drug for controlled release therefrom
US4070347A (en) 1976-08-16 1978-01-24 Alza Corporation Poly(orthoester) co- and homopolymers and poly(orthocarbonate) co- and homopolymers having carbonyloxy functionality
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4290905A (en) 1979-12-26 1981-09-22 Kabushiki Kaisha Suwa Seikosha Ester compound
ATE12224T1 (de) 1981-11-17 1985-04-15 Kabivitrum Ab Verbindungen mit antifibrinolytischer wirksamkeit.
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4421736A (en) 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4426391A (en) 1982-09-15 1984-01-17 Merck & Co., Inc. [(Alkoxycarbonyl)oxy]alkyl esters of methyldopa
IL67445A (en) 1982-12-09 1985-11-29 Teva Pharma Ethoxycarbonyloxy ethyl esters of non-steroidal anti-inflammatory carboxylic acids
US4721613A (en) 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
US4760057A (en) 1983-06-23 1988-07-26 Merck & Co., Inc. (Acyloxyalkoxy)carbonyl derivatives as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4916230A (en) * 1984-07-02 1990-04-10 Merck & Co., Inc. Process for preparing novel N-(acyloxy-alkoxy)carbonyl derivatives useful as bioreversible prodrug moieties for primary and secondary amine functions in drugs
US4820523A (en) 1986-04-15 1989-04-11 Warner-Lambert Company Pharmaceutical composition
US4752470A (en) 1986-11-24 1988-06-21 Mehta Atul M Controlled release indomethacin
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
US4816263A (en) 1987-10-02 1989-03-28 Alza Corporation Dosage form for treating cardiovascular diseases comprising isradipine
US4853229A (en) 1987-10-26 1989-08-01 Alza Corporation Method for adminstering tiny pills
DE69023844T2 (de) 1989-09-06 1996-06-20 Merck & Co Inc Acyloxymethylester der Bisphonsäuren als Knochenresorptions-Inhibitoren.
GB9001405D0 (en) 1990-01-22 1990-03-21 Leo Pharm Prod Ltd New intermediates,their production and use
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5229135A (en) 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
EP0585130B1 (en) 1992-08-27 1998-01-28 Shiseido Company Limited External preparation for skin containing a depigmentation agent
SE9300013L (sv) 1992-12-30 1994-07-01 Kabi Pharmacia Ab Nytt förfarande och mellanprodukter för framställning av pro- läkemedel
JPH07165555A (ja) 1993-12-09 1995-06-27 Shiseido Co Ltd 皮膚外用剤
US5466811A (en) 1994-07-18 1995-11-14 Merck & Co., Inc. Dioxolenylmethyl carbamates pro moieties for amine drugs
US5684018A (en) 1994-12-13 1997-11-04 Merck & Co., Inc. Acyloxyisopropyl carbamates as prodrugs for amine drugs
DE69531957T2 (de) 1994-12-19 2004-08-12 Daiichi Pharmaceutical Co., Ltd. Granulat-präparate mit kontinuierlicher freisetzung und verfahren zur herstellung
JP3483988B2 (ja) 1995-06-01 2004-01-06 株式会社資生堂 皮膚外用剤
JP3814881B2 (ja) 1996-08-07 2006-08-30 味の素株式会社 シクロヘキシルアミノ酸類の製造方法
US6375987B1 (en) 1996-10-01 2002-04-23 Gattefossé, S.A. Process for the manufacture of pharmaceutical composition with modified release of active principle comprising the matrix
FR2779651B1 (fr) 1998-06-16 2001-04-20 Gattefosse Ets Sa Procede pour la fabrication de comprimes a liberation prolongee de principe(s) actif(s) presentant une cinetique de dissolution d'ordre zero
US6171615B1 (en) 1998-07-06 2001-01-09 Gattefoss{acute over (e)} Sustained release theophylline formulations, excipient systems and methods of production
WO2001005813A1 (en) 1999-07-15 2001-01-25 Eli Lilly And Company Pseudomycin prodrugs
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
ATE540678T1 (de) * 2001-06-11 2012-01-15 Xenoport Inc Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
US7232924B2 (en) 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003077902A1 (en) 2002-02-19 2003-09-25 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
ITMI20030882A1 (it) 2003-04-30 2004-11-01 Eni Spa Metodo per inibire l'acidificazione biologica di acque in contatto con materiali contenenti zolfo
WO2005010011A2 (en) 2003-07-15 2005-02-03 Xenoport, Inc. Methods of synthesis of acyloxyalkyl compounds
US7860074B2 (en) * 2003-07-31 2010-12-28 Motorola, Inc. Method and apparatus for allocating communication resources
KR20110097942A (ko) * 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
PT1677767E (pt) 2003-10-14 2011-10-13 Xenoport Inc Forma cristalina de análogo de ácido gama-aminobutírico
EP2371815A1 (en) 2003-12-30 2011-10-05 XenoPort, Inc. Sythesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
CA2584338C (en) 2004-11-04 2013-08-06 Xenoport, Inc. Gabapentin prodrug sustained release oral dosage forms
WO2007002013A2 (en) 2005-06-20 2007-01-04 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US7332924B2 (en) 2005-11-15 2008-02-19 Agere Systems, Inc. Embedded test circuitry and a method for testing a semiconductor device for breakdown, wearout or failure
US7770070B2 (en) * 2007-06-21 2010-08-03 Xerox Corporation Test automation via RFID technology
WO2010017498A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing n-hydroxysuccinimidyl carbonates
WO2010017504A1 (en) 2008-08-07 2010-02-11 Xenoport, Inc. Methods of synthesizing 1-(acyloxy)-alkyl carbamate prodrugs
CN102186804A (zh) 2008-10-20 2011-09-14 克塞诺波特公司 合成左旋多巴酯前药的方法
AU2010221167B2 (en) 2009-03-06 2014-04-03 Xenoport, Inc. Oral dosage forms having a high loading of a gabapentin prodrug

Also Published As

Publication number Publication date
AU2006262386A1 (en) 2007-01-04
ES2345784T3 (es) 2010-10-01
US7777070B2 (en) 2010-08-17
JP4938771B2 (ja) 2012-05-23
US20070027210A1 (en) 2007-02-01
AU2006262386B2 (en) 2012-02-02
JP2008546717A (ja) 2008-12-25
US20080153898A1 (en) 2008-06-26
US20110009483A1 (en) 2011-01-13
ATE469880T1 (de) 2010-06-15
EP1919859A2 (en) 2008-05-14
ZA200800311B (en) 2009-04-29
US7351740B2 (en) 2008-04-01
US8372881B2 (en) 2013-02-12
CA2612292C (en) 2013-09-03
IL188172A (en) 2013-02-28
EP1919859B1 (en) 2010-06-02
HK1117824A1 (en) 2009-01-23
CN101253148A (zh) 2008-08-27
DE602006014694D1 (de) 2010-07-15
WO2007002013A3 (en) 2007-03-22
CA2612292A1 (en) 2007-01-04
US20100036148A1 (en) 2010-02-11
NO20076508L (no) 2008-03-17
NZ564468A (en) 2011-05-27
WO2007002013A2 (en) 2007-01-04
CN101253148B (zh) 2013-01-02
IL188172A0 (en) 2008-03-20
US7592369B2 (en) 2009-09-22

Similar Documents

Publication Publication Date Title
US7592369B2 (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use
US10385014B2 (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
US20090124582A1 (en) Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use
JP2011256182A (ja) アシルオキシアルキル・カルバメート・プロドラッグ、合成及び使用の方法
HK1117824B (en) Acyloxyalkyl carbamate prodrugs of tranexamic acid and use
HK1090912B (en) Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
EP2354120A1 (en) Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
BRPI0413756B1 (pt) Composition, methods for treating or avoiding spasicity or a symptom of spasicity, gastro-esophageal reflux disease, drug addiction, vicious or abuse of alcohol, or vicious in or ability of nicotine, and tosse or emems in a patient and, pharmaceutical composition

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080118

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20110620

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130321

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20130901

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee